News for Panagene Inc. (046210.KQ)

Published at

Jan 27, 2025 7:03 PM

by manilatimes.net

mixed

mixed

Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board

**media[525483]**

046210.KQ 028300.KQ

Read more →
Published at

Dec 3, 2024 3:00 PM

by gurufocus.com

positive

positive

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential bes

RLAY MC 046210.KQ 028300.KQ

Read more →